366 related articles for article (PubMed ID: 33176972)
21. PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer.
Chabanon RM; Morel D; Eychenne T; Colmet-Daage L; Bajrami I; Dorvault N; Garrido M; Meisenberg C; Lamb A; Ngo C; Hopkins SR; Roumeliotis TI; Jouny S; Hénon C; Kawai-Kawachi A; Astier C; Konde A; Del Nery E; Massard C; Pettitt SJ; Margueron R; Choudhary JS; Almouzni G; Soria JC; Deutsch E; Downs JA; Lord CJ; Postel-Vinay S
Cancer Res; 2021 Jun; 81(11):2888-2902. PubMed ID: 33888468
[TBL] [Abstract][Full Text] [Related]
22. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
[TBL] [Abstract][Full Text] [Related]
23. Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer.
Gout J; Perkhofer L; Morawe M; Arnold F; Ihle M; Biber S; Lange S; Roger E; Kraus JM; Stifter K; Hahn SA; Zamperone A; Engleitner T; Müller M; Walter K; Rodriguez-Aznar E; Sainz B; Hermann PC; Hessmann E; Müller S; Azoitei N; Lechel A; Liebau S; Wagner M; Simeone DM; Kestler HA; Seufferlein T; Wiesmüller L; Rad R; Frappart PO; Kleger A
Gut; 2021 Apr; 70(4):743-760. PubMed ID: 32873698
[TBL] [Abstract][Full Text] [Related]
24. ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition.
Gilardini Montani MS; Prodosmo A; Stagni V; Merli D; Monteonofrio L; Gatti V; Gentileschi MP; Barilà D; Soddu S
J Exp Clin Cancer Res; 2013 Nov; 32(1):95. PubMed ID: 24252502
[TBL] [Abstract][Full Text] [Related]
25. PARP inhibitors in advanced prostate cancer: when to use them?
Díaz-Mejía N; García-Illescas D; Morales-Barrera R; Suarez C; Planas J; Maldonado X; Carles J; Mateo J
Endocr Relat Cancer; 2021 Jul; 28(8):T79-T93. PubMed ID: 34256353
[TBL] [Abstract][Full Text] [Related]
26. Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial.
Carreira S; Porta N; Arce-Gallego S; Seed G; Llop-Guevara A; Bianchini D; Rescigno P; Paschalis A; Bertan C; Baker C; Goodall J; Miranda S; Riisnaes R; Figueiredo I; Ferreira A; Pereira R; Crespo M; Gurel B; Nava Rodrigues D; Pettitt SJ; Yuan W; Serra V; Rekowski J; Lord CJ; Hall E; Mateo J; de Bono JS
Cancer Discov; 2021 Nov; 11(11):2812-2827. PubMed ID: 34045297
[TBL] [Abstract][Full Text] [Related]
27. ATM depletion induces proteasomal degradation of FANCD2 and sensitizes neuroblastoma cells to PARP inhibitors.
Parvin S; Akter J; Takenobu H; Katai Y; Satoh S; Okada R; Haruta M; Mukae K; Wada T; Ohira M; Ando K; Kamijo T
BMC Cancer; 2023 Apr; 23(1):313. PubMed ID: 37020276
[TBL] [Abstract][Full Text] [Related]
28. Synergism between ATM and PARP1 Inhibition Involves DNA Damage and Abrogating the G
Mak JPY; Ma HT; Poon RYC
Mol Cancer Ther; 2020 Jan; 19(1):123-134. PubMed ID: 31597711
[TBL] [Abstract][Full Text] [Related]
29. 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.
Hong R; Ma F; Zhang W; Yu X; Li Q; Luo Y; Zhu C; Jiang W; Xu B
BMC Cancer; 2016 Sep; 16(1):725. PubMed ID: 27613518
[TBL] [Abstract][Full Text] [Related]
30. PLX038: A Long-Acting Topoisomerase I Inhibitor With Robust Antitumor Activity in ATM-Deficient Tumors and Potent Synergy With PARP Inhibitors.
Thomas A; Fontaine SD; Diolaiti ME; Desai P; Kumar R; Takahashi N; Sciuto L; Nichols S; Ashworth A; Feng FY; Ashley GW; Nguyen M; Pommier Y; Santi DV
Mol Cancer Ther; 2022 Nov; 21(11):1722-1728. PubMed ID: 35999657
[TBL] [Abstract][Full Text] [Related]
31. The Role of PARP Inhibitors in the Treatment of Prostate Cancer: Recent Advances in Clinical Trials.
Xia M; Guo Z; Hu Z
Biomolecules; 2021 May; 11(5):. PubMed ID: 34066020
[TBL] [Abstract][Full Text] [Related]
32. Targeting PARP in Prostate Cancer: Novelty, Pitfalls, and Promise.
Palmbos PL; Hussain MH
Oncology (Williston Park); 2016 May; 30(5):377-85. PubMed ID: 27188668
[TBL] [Abstract][Full Text] [Related]
33. Targeting the replication stress response through synthetic lethal strategies in cancer medicine.
Ngoi NYL; Pham MM; Tan DSP; Yap TA
Trends Cancer; 2021 Oct; 7(10):930-957. PubMed ID: 34215565
[TBL] [Abstract][Full Text] [Related]
34. The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma.
Shi Q; Shen LY; Dong B; Fu H; Kang XZ; Yang YB; Dai L; Yan WP; Xiong HC; Liang Z; Chen KN
Cancer Lett; 2018 Sep; 432():56-68. PubMed ID: 29890208
[TBL] [Abstract][Full Text] [Related]
35. Niraparib Shows Superior Tissue Distribution and Efficacy in a Prostate Cancer Bone Metastasis Model Compared with Other PARP Inhibitors.
Snyder LA; Damle R; Patel S; Bohrer J; Fiorella A; Driscoll J; Hawkins R; Stratton CF; Manning CD; Tatikola K; Tryputsen V; Packman K; Mamidi RNVS
Mol Cancer Ther; 2022 Jul; 21(7):1115-1124. PubMed ID: 35499386
[TBL] [Abstract][Full Text] [Related]
36. DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities.
Dhawan M; Ryan CJ; Ashworth A
Oncologist; 2016 Aug; 21(8):940-5. PubMed ID: 27317574
[TBL] [Abstract][Full Text] [Related]
37. PARP Inhibitors in Prostate Cancer—The Preclinical Rationale and Current Clinical Development.
Virtanen V; Paunu K; Ahlskog JK; Varnai R; Sipeky C; Sundvall M
Genes (Basel); 2019 Jul; 10(8):. PubMed ID: 31357527
[TBL] [Abstract][Full Text] [Related]
38. ATR Inhibition Induces CDK1-SPOP Signaling and Enhances Anti-PD-L1 Cytotoxicity in Prostate Cancer.
Tang Z; Pilié PG; Geng C; Manyam GC; Yang G; Park S; Wang D; Peng S; Wu C; Peng G; Yap TA; Corn PG; Broom BM; Thompson TC
Clin Cancer Res; 2021 Sep; 27(17):4898-4909. PubMed ID: 34168048
[TBL] [Abstract][Full Text] [Related]
39. ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors.
Williamson CT; Muzik H; Turhan AG; Zamò A; O'Connor MJ; Bebb DG; Lees-Miller SP
Mol Cancer Ther; 2010 Feb; 9(2):347-57. PubMed ID: 20124459
[TBL] [Abstract][Full Text] [Related]
40. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.
Beltran H; Yelensky R; Frampton GM; Park K; Downing SR; MacDonald TY; Jarosz M; Lipson D; Tagawa ST; Nanus DM; Stephens PJ; Mosquera JM; Cronin MT; Rubin MA
Eur Urol; 2013 May; 63(5):920-6. PubMed ID: 22981675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
